CR-ABL1 Tyrosine Kinase Complex Signaling Transduc... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

CR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemi

Full text
Author(s):
Amarante-Mendes, Gustavo P. [1, 2] ; Rana, Aamir [1, 3] ; Datoguia, Tarcila Santos [4] ; Hamerschlak, Nelson [4] ; Brumatti, Gabriela [5, 6]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508000 Sao Paulo - Brazil
[2] Inst Invest Imunol, Inst Nacl Ciencia Tecnol INCT, BR-05508000 Sao Paulo - Brazil
[3] Beckman Res Inst City Hope, Dept ImmunoOncol, Duarte, CA 91010 - USA
[4] Hosp Israelita Albert Einstein, BR-05652900 Sao Paulo - Brazil
[5] Walter & Eliza Hall Inst Med Res, Inflammat Div, Melbourne, Vic 3052 - Australia
[6] Univ Melbourne, Dept Med Biol, Melbourne, Vic 3010 - Australia
Total Affiliations: 6
Document type: Journal article
Source: HARMACEUTIC; v. 14, n. 1 JAN 2022.
Web of Science Citations: 0
Abstract

The constitutively active BCR-ABL1 tyrosine kinase, found in t(9;22)(q34;q11) chromosomal translocation-derived leukemia, initiates an extremely complex signaling transduction cascade that induces a strong state of resistance to chemotherapy. Targeted therapies based on tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, nilotinib, bosutinib, and ponatinib, have revolutionized the treatment of BCR-ABL1-driven leukemia, particularly chronic myeloid leukemia (CML). However, TKIs do not cure CML patients, as some develop TKI resistance and the majority relapse upon withdrawal from treatment. Importantly, although BCR-ABL1 tyrosine kinase is necessary to initiate and establish the malignant phenotype of Ph-related leukemia, in the later advanced phase of the disease, BCR-ABL1-independent mechanisms are also in place. Here, we present an overview of the signaling pathways initiated by BCR-ABL1 and discuss the major challenges regarding immunologic/pharmacologic combined therapies. (AU)

FAPESP's process: 15/09568-5 - Role of autophagy in the control of infection by Trypanosoma cruzi and the influence of the innate immunity receptors in this process
Grantee:Kely Catarine Matteucci
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 18/25395-1 - Role of RASSF9 in melanoma using the CRISPR/Cas9 system
Grantee:João Gustavo Pessini Amarante Mendes
Support Opportunities: Regular Research Grants